NCT02661594View on ClinicalTrials.gov

Thorough QT Study of Intravenous Amisulpride

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Healthy
Interventions
DRUG

APD421 5 mg

Therapeutic dose of amisulpride

DRUG

APD421 40 mg

Supra-therapeutic dose of amisulpride

DRUG

Moxifloxacin

Positive control for assay sensitivity

DRUG

Placebo

Placebo comparator to establish baseline for calculating change in QTcF

Sponsors

Lead Sponsor

Acacia Pharma Ltd
All Listed Sponsors
lead

Acacia Pharma Ltd

INDUSTRY